Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-05-06 | Amended | $8,648,469 | $4,983,904 | Equity Only | 06b | SEC link |
| 2025-04-15 | Amended | $3,664,565 | $150,000 | Equity Only | 06b | SEC link |
| 2025-03-06 | New | $3,514,565 | $3,514,565 | Equity Only | 06b | SEC link |
| 2024-03-27 | New | $2,007,000 | $2,007,000 | Equity Only | 06b | SEC link |
| 2023-07-24 | New | $1,457,000 | $1,457,000 | Debt Only | 06b | SEC link |
| 2023-03-24 | Amended | $4,500,000 | $1,955,000 | Equity Only | 06b | SEC link |
| 2022-09-22 | New | $2,545,000 | $2,545,000 | Equity Only | 06b | SEC link |
| 2021-11-10 | New | $4,200,000 | $4,200,000 | Equity Only | 06b | SEC link |
| 2021-04-28 | Amended | $2,875,000 | $2,050,000 | Equity Only | 06b | SEC link |
| 2021-01-20 | New | $825,000 | $825,000 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Enrique Carrazana | Director |
| Roy Freeman | Director |
| Christopher Gibbons | Director |
| Peter Harris | Director, Executive |
| Todd Levine | Director, Executive |
| Richard J. Morello | Director, Executive |
| Jack Seaver | Director |